R. Caporali, R. Ravasio, P. Raimondo, and F. Salaffi, “Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy”, Grhta, vol. 8, no. 1, pp. 69–79, Jul. 2021.